The Adaptor Protein MITA Links Virus-Sensing Receptors to IRF3 Transcription Factor Activation  by Zhong, Bo et al.
Immunity
ArticleThe Adaptor Protein MITA Links Virus-Sensing
Receptors to IRF3 Transcription Factor Activation
Bo Zhong,1 Yan Yang,1 Shu Li,1 Yan-Yi Wang,1 Ying Li,1 Feici Diao,1 Caoqi Lei,1 Xiao He,1 Lu Zhang,1 Po Tien,1
and Hong-Bing Shu1,*
1College of Life Sciences, Wuhan University, Wuhan 430072, China
*Correspondence: shuh@whu.edu.cn
DOI 10.1016/j.immuni.2008.09.003SUMMARY
Viral infection triggers activation of transcription fac-
tors such as NF-kB and IRF3, which collaborate to
induce type I interferons (IFNs) and elicit innate anti-
viral response. Here, we identified MITA as a critical
mediator of virus-triggered type I IFN signaling by ex-
pression cloning. Overexpression of MITA activated
IRF3, whereas knockdown of MITA inhibited virus-
triggered activation of IRF3, expression of type I
IFNs, and cellular antiviral response. MITA was found
to localize to the outer membrane of mitochondria
and to be associated with VISA, a mitochondrial pro-
tein that acts as an adaptor in virus-triggered signal-
ing. MITA also interacted with IRF3 and recruited the
kinase TBK1 to the VISA-associated complex. MITA
was phosphorylated by TBK1, which is required for
MITA-mediated activation of IRF3. Our results sug-
gest that MITA is a critical mediator of virus-triggered
IRF3 activation and IFN expression and further
demonstrate the importance of certain mitochondrial
proteins in innate antiviral immunity.
INTRODUCTION
Viral infection triggers a series of signaling events that lead to
induction of type I interferons (IFNs), including IFN-b and IFN-a
family cytokines (Akira et al., 2006; Fitzgerald et al., 2003;
Hiscott, 2007; Honda et al., 2006; Katze et al., 2002). Type I
IFNs activate the JAK-STAT signal transduction pathways, lead-
ing to transcriptional induction of a wide range of genes, such as
those that encode IRFs, PKR, IP10, ISGs, and OAS. These
downstream gene products mediate inhibition of viral replication
and clearance of virus-infected cells, leading to innate antiviral
response (Durbin et al., 2000; Levy and Garcia-Sastre, 2001;
Levy and Marie, 2004).
Transcriptional induction of type I IFN genes requires the coor-
dinate activation of multiple transcription factors and their coop-
erative assembly into transcriptional enhancer complexes
in vivo. For example, the enhancer of the IFN-b gene contains
a kB site recognized by NF-kB, a site for ATF-2-c-Jun, and two
IRF-E (also known as PRDIII or ISRE) elements recognized by
phosphorylated IRF3 and/or IRF7. It has been shown that tran-
scriptional activation of the IFN-b gene requires coordinate and
cooperative assembly of an enhanceosome that contains all of538 Immunity 29, 538–550, October 17, 2008 ª2008 Elsevier Inc.these transcription factors (Honda et al., 2006; Maniatis et al.,
1998; Wathelet et al., 1998).
Studies during the past decade have led to breakthrough
advances on the virus-triggered type I IFN signaling pathways.
The host has developed at least two distinct mechanisms for viral
RNA recognition, which represents the first step of innate antivi-
ral response. One is mediated by Toll-like receptors (TLRs), such
as TLR3, which recognizes viral dsRNA released by infected
cells (Alexopoulou et al., 2001). Engagement of TLR3 by dsRNA
triggers TRIF (an adaptor of the TLR pathway)-mediated signal-
ing pathways, thereby leading to IRF3 and NF-kB activation (Han
et al., 2004; Oshiumi et al., 2003; Yamamoto et al., 2003; Yama-
moto et al., 2002). The second mechanism involves two RNA
helicase proteins, RIG-I and MDA5, which function as cytoplas-
mic viral RNA sensors (Andrejeva et al., 2004; Yoneyama et al.,
2004). Both RIG-I and MDA5 contain two CARDmodules at their
N terminus and a DexD/H-box helicase domain at their C termi-
nus. The helicase domains of RIG-I and MDA5 serve as intracel-
lular viral RNA receptors, whereas the CARD modules are
responsible for transmitting signals to downstream CARD-
containing adaptor protein VISA (also known as MAVS, IPS-1,
and Cardif) (Hornung et al., 2006; Kato et al., 2006; Kawai
et al., 2005; Meylan et al., 2005; Pichlmair et al., 2006; Seth
et al., 2005; Xu et al., 2005). Gene-deletion studies indicate
that VISA is required for the activation of IRF3 and NF-kB, and
VISA-deficient mice exhibit severe deficiency in induction of
type I IFNs and proinflammatory cytokines and are susceptible
to RNA virus infection (Kumar et al., 2006; Sun et al., 2006). Inter-
estingly, the C terminus of VISA contains a transmembrane do-
main, which targets it to the outer membrane of mitochondria.
The mitochondrial localization of VISA is essential for triggering
downstream signaling, indicating a critical link between mito-
chondria and innate antiviral immunity (Seth et al., 2005).
Various studies have demonstrated that the IkB kinase (IKK)
family members are critically involved in virus-triggered and
VISA-mediated induction of type I IFNs. Although IKKa and
IKKb are essential for virus-triggered NF-kB activation, the non-
canonical IKK family members TBK1 and IKK3 are responsible
for phosphorylating and activating IRF3 and IRF7 (Fitzgerald
et al., 2003; Hemmi et al., 2004; Matsui et al., 2006). The mech-
anisms on how VISA signals the activation of canonical and non-
canonical IKK family members, however, are less clear. VISA can
interact with tumor necrosis factor (TNF) receptor-associated
factor 6 (TRAF6) through its conserved TRAF6-binding motifs.
VISA-mediated NF-kB but not IRF3 activation is diminished in
TRAF6-deficient fibroblasts, suggesting that TRAF6 acts down-
stream of VISA in the NF-kB but not IRF3-activation pathway
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MITA Mediates Cellular Antiviral ResponseFigure 1. Sequence and Expression Analysis of MITA
(A) Alignment of human and mouse MITA amino acid sequences. Four putative transmembrane regions (TM) are indicated by bold lines. The asterisk marks the
serine residue of MITA whose phosphorylation is important for its function.
(B) RNA blot analysis of human MITA mRNA expression.
(C) Immunoblot analysis of humanMITA expression in the indicated cell lines. Whole-cell lysates from the indicated cells were analyzed by immunoblotting with a
mouse polyclonal antibody against humanMITA (aa 221–379). Ten times less lysate was loaded for the Flag-MITA-transfected 293 cell sample. The experiments
were repeated for three times with similar results.(Xu et al., 2005). Other studies indicate that the TNF receptor
associated signaling components, including TRADD, FADD, and
RIP, interact with VISA and are required for VISA-mediated
NF-kB and IRF3 activation (Kawai et al., 2005; Michallet et al.,
2008). Gene-deletion studies also suggest a role of TRAF3 in
virus-triggered induction of type I IFNs (Oganesyan et al., 2006;
Saha et al., 2006).
In this study, we identified an uncharacterized protein, which
we designate as MITA. MITA localized to the outer membrane
of mitochondria and associated with VISA. MITA acted as an
adaptor protein to recruit TBK1 and IRF3 to VISA, and knock-
down of MITA abolished virus-triggered IRF3 activation, IFNB1
expression, and cellular antiviral response. Our findings provide
amolecular mechanism on VISA-mediated IRF3-activation path-
way and further illustrate the importance of certain mitochondrial
proteins in innate antiviral immunity.
RESULTS
Identification of MITA by Expression Cloning
To identify additional proteins involved in virus-triggered IRF3
activation, we performed expression cloning experiments usinga reporter construct driven by five copies of IRF-E of the ISG54
gene promoter, which has previously been shown to be
activated by IRF3 (Nakaya et al., 2001; Navarro et al., 1998).
From23 105 clones of a human spleen cDNA library screened,
we identified seven clones that could activate IRF-E in 293 cells.
Sequencing analysis indicated that these clones encode IRF1,
IRF3, IRF7, and an uncharacterized protein identified by the
NIH full-length cDNA project (GenBank accession number
NM_198282). On the basis of its functions described below,
we designated this protein as MITA (forMediator of IRF3 Activa-
tion). HumanMITA contains 379 amino acid residues and shares
69% sequence identity at the amino acid level with its mouse
ortholog (Figure 1A), but has no substantial homology with other
proteins. Structural analysis with several programs indicated
that MITA contains four putative transmembrane regions
but lacks other recognizable motifs or domains (Figure 1A).
RNA blot analysis indicated that MITA is ubiquitously expressed
as a2.4 kb transcript in all examined human tissues (Figure 1B).
Immunoblot analysis indicated that MITA is expressed as
a 42 kDa protein in human 293 and A549 cells and to a much
lower amount in Huh7 cells (Figure 1C and Figure S1 available
online).Immunity 29, 538–550, October 17, 2008 ª2008 Elsevier Inc. 539
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MITA Mediates Cellular Antiviral ResponseFigure 2. MITA Activates IRF-E but Not NF-kB or IFN-b Promoter
(A) MITA activates IRF-E in a dose-dependent manner in 293 cells. 293 cells (13 105) were transfected with IRF-E plasmids (0.1 mg) and the indicated amount of
expression plasmid of MITA. Luciferase assays were performed 24 hr after transfection. Graphs show mean ± SD, n = 3.
(B) Comparison of MITA-, IRF3-, and VISA-mediated activation of IRF-E, NF-kB, and the IFN-b promoter. 293 cells (13 105) were transfected with the indicated
reporter (0.1 mg) and expression (0.1 mg each) plasmids. Luciferase assays were performed 20 hr after transfection. Graphs show mean ± SD, n = 3.
(C) Overexpression of MITA results in IRF3 nuclear translocation. 293 cells (2 3 106) were transfected with the indicated plasmids (8 mg each). About 14 hr after
transfection, nuclear extracts (two panels, top) and nonnuclear fractions (three panels, bottom) were prepared and analyzed with the indicated antibodies. The
experiments were repeated for three times with similar results.
(D) MITA-mediated IRF-E activation is inhibited by IRF3 and IRF7 mutants. Reporter assays were performed similarly as in (B). Graphs show mean ± SD, n = 3.
(E) Overexpression ofMITA induces expression of endogenous ISG15 and ISG56 but not IFNB1 in 293 cells. 293 cells (23 105) were transfected with the indicated
expression plasmids (2 mg each) for 20 hr before RT-PCR for the indicated genes was performed. The experiments were repeated for three times with similar
results.Overexpression of MITA Activates IRF3
To confirm that MITA is capable of activating IRF-E, we con-
structed MITA expression plasmids independently of the original
clone identified in the expression screens. As shown in Figure 2A,
overexpression of MITA activated IRF-E in a dose-dependent
manner in 293 cells in reporter assays. The degree of MITA-
mediated IRF-E activation was similar to that of IRF3 but mark-
edly lower than that of VISA (Figure 2B), with these proteins
expressed at similar amounts (Figure S2). Consistently, overex-
pression of MITA caused translocation of IRF3 into the nucleus
(Figure 2C), whereas MITA-mediated IRF-E activation was
inhibited by dominant-negative mutants of IRF3 and IRF7 (Fig-
ure 2D). These data suggest that MITA activates IRF-E through
IRF3 and IRF7.
Because viral infection also activates NF-kB, we determined
whether MITA can activate NF-kB. As shown in Figure 2B,
MITA did not activate NF-kB in reporter assays. Consistently,
MITA did not activate the IFN-b promoter (Figure 2B), which540 Immunity 29, 538–550, October 17, 2008 ª2008 Elsevier Inc.needs cooperation of NF-kB and IRF3 for activation. Further-
more, overexpression of MITA induced endogenous expression
of two IRF-E-dependent antiviral genes ISG15 and ISG56
(Nakaya et al., 2001; Wathelet et al., 1987) but failed to induce
endogenous expression of IFNB1 (Figure 2E). These data sug-
gest that overexpression of MITA activates IRF3.
MITA Is Required for Virus-Triggered IRF3 Activation
and Cellular Antiviral Response
We next determined whether endogenous MITA is required for
virus-triggered IRF3 activation and type I IFN induction. We uti-
lized three MITA-RNAi plasmids that could substantially inhibit
the expression of transfected or endogenous MITA (Figure 3A).
As shown in Figure 3B, all three MITA-RNAi plasmids potently
inhibited Sendai virus (SeV)-induced IRF-E activation (The #2
MITA-RNAi plasmid was used for all the experiments described
below. Similar results were obtained with the #1 MITA-RNAi
plasmid.). Knockdown of MITA also inhibited SeV-induced
Immunity
MITA Mediates Cellular Antiviral ResponseIRF3 dimerization and phosphorylation (Figure 3C), which are
hallmarks of IRF3 activation. Although MITA was expressed at a
low level in Huh7 cells, it was still required for SeV-induced IRF-
E activation in these cells (Figure S3A). Interestingly, although
overexpression of MITA did not activate NF-kB, knockdown of
MITA inhibited virus-triggered NF-kB activation (Figure 3D), sug-
gesting a potential crosstalk between virus-triggered NF-kB and
IRF3-activation pathways at theMITA level. As expected, knock-
downofMITA inhibited SeV-triggered activation of the IFN-b pro-
moter (Figure 3E), as well as endogenous expression of ISG15,
ISG56, and IFNB1 (Figure 3F). In similar experiments, knock-
down of MITA did not affect TNF- or IL-1-induced NF-kB activa-
tion (Figure 3G). These data suggest that MITA is a critical medi-
ator of virus-triggered activation of IRF3 and expression of IFNB1
and other IRF3-dependent genes.
Because MITA is critically involved in virus-triggered expres-
sion of IRF3-dependent genes, we determined whether MITA
plays a role in cellular antiviral response. In plaque assays, over-
expression of MITA significantly inhibited VSV replication in
a dose-dependent manner in 293 cells (p < 0.001), whereas
knockdown of MITA had an opposite effect (p < 0.01) (Figures
3H and 3I). Similarly, knockdown of MITA also inhibited SeV-in-
duced activation of the IFN-b promoter aswell as VSV replication
in HeLa cells (Figures S3B and S3C). Collectively, these results
suggest that MITA is required for efficient cellular antiviral re-
sponse.
To determine whether MITA is required for intracellular
dsRNA-induced antiviral response, we performed two lines of
experiments. In reporter assays, knockdown of MITA inhibited
intracellular poly(I:C)-induced IRF-E activation (Figure S4A).
Consistently, plaque assays indicated knockdown of MITA
inhibited intracellular poly(I:C)-induced antiviral response (Fig-
ure S4B). Similarly, knockdown of MITA also inhibited B-DNA-
induced activation of IRF-E, NF-kB, and the IFN-b promoter
(Figure S4C). These data suggest that MITA is also required for
intracellular dsRNA- and B-DNA-induced antiviral response.
MITA Is Localized to the Outer Membrane
of Mitochondria
MITA contains multiple putative transmembrane regions and
previous studies have shown that VISA is located at the outer
membrane of mitochondria (Seth et al., 2005). Therefore, we de-
termined whether MITA is also localized to the mitochondria by
cell fractionation and immunoblot analysis (Figure 4A). We found
endogenous MITA exclusively existed in the mitochondrial frac-
tion, which also contained VISA and the mitochondrial protein
AIF (Figure 4B). MITA was undetectable in other nonmitochon-
drial fractions, including the endoplasmic reticulum, cytosol,
and nucleus (Figure 4B and data not shown). Confocal micros-
copy indicated that GFP-tagged MITA is colocalized with the mi-
tochondrial stain MitoTracker Red no matter the tag is attached
to its N or C terminus (Figure 4C). Deletion analysis indicated that
the third transmembrane region (aa 112–135) of MITA was
important for its mitochondrial localization (Figure S5). Results
from trypsin-protection assays with purified mitochondria
indicated that both MITA and VISA were sensitive to trypsin
treatment, whereas the mitochondrial inner-membrane protein
COX4 was protected (Figure 4D). These data suggest that MITA
is localized to the outer membrane of mitochondria.MITA Interacts with VISA and Is Recruited to RIG-I upon
Viral Infection
Because both MITA and VISA are localized to the outer mem-
brane of mitochondria and required for virus-triggered induction
of type I IFNs, we determined whether MITA interacts with VISA.
Transient transfection and coimmunoprecipitation experiments
indicated that MITA interacts with VISA (Figure 5A). Endogenous
coimmunoprecipitation experiments indicated that MITA consti-
tutively interacts with VISA in the presence or absence of viral
infection (Figure 5B). Previously, it has been demonstrated
that a fraction of VISA is redistributed to insoluble fraction after
viral infection (Seth et al., 2005). We found that a fraction of MITA
is also redistributed to insoluble fraction after SeV infection
(Figure S6). These observations suggest that VISA-MITA-medi-
ated signaling may be initiated from the insoluble fraction.
Domain-mapping experiments indicated that theC terminus of
VISA (aa 360–540) and the region spanning the third and fourth
transmembrane domains of MITA (aa 111–160) were required
for their interaction (Figure 5C). Interestingly, the C-terminal frag-
ment of VISA contained the transmembrane domain (Seth et al.,
2005) and was sufficient for IRF-E activation (Xu et al., 2005),
whereas aa 111–160 of MITA was important for its mitochondrial
localization and oligomerization (Figures S5 and S7). In reporter
assays, knockdown of VISA by RNAi inhibited RIG-I- but not
MITA-mediated IRF-E activation (Figure 5D), whereas knock-
down of MITA inhibited VISA- but not TRIF- and TBK1-mediated
IRF-E activation (Figure 5E). These data suggest that VISA
signals IRF-E activation through MITA.
VISA is an adaptor for signaling triggered by the viral RNA sen-
sor RIG-I. We determined whether MITA is associated with RIG-I
through VISA. Inmammalian overexpression system, RIG-I inter-
acted with MITA weakly, probably through endogenous VISA.
This interaction was enhanced by ectopically expressed VISA
(Figure 5F). In untransfected cells, endogenous RIG-I interacted
with MITA in viral-infection-dependent manner, and this interac-
tion was diminished by knockdown of VISA (Figure 5G). Consis-
tently, we found that a small fraction of RIG-I is localized to mito-
chondria upon viral infection (Figure 4B). These data suggest that
RIG-I is recruited to the VISA-MITA complex on themitochondria
upon viral infection.
MITA Links IRF3 and TBK1 to VISA
Previous studies have demonstrated that various proteins are
involved in VISA-mediated IRF3 and IRF7 activation, including
TBK1, IKK3, TRAF3, TRADD, FADD, and RIP. In addition, it has
been suggested that VISA induces IRF3 activation through
TBK1 in most cell types and IKK3 under certain conditions
(Hemmi et al., 2004). In transient transfection and coimmunopre-
cipitation experiments, MITA interacted with TBK1, IKK3, IRF3,
and IRF7 but not with IKKa or IRF9 (Figure 6A). MITA
also interacted with TRAF3 but not with TRADD, FADD, and RIP
(Figure S7 and data not shown). Interestingly, endogenous
coimmunoprecipitation experiments indicated that MITA consti-
tutively interacted with IRF3, and this interaction was slightly
enhanced after viral infection, although its interaction with TBK1
was viral-infection-dependent in untransfected cells (Figure 6B).
Consistently, we found that a fraction of IRF3 was constitutively
localized to themitochondria, whereas a fraction of TBK1was re-
cruited to the mitochondria upon viral infection (Figure 4B). InImmunity 29, 538–550, October 17, 2008 ª2008 Elsevier Inc. 541
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MITA Mediates Cellular Antiviral ResponseFigure 3. MITA Is Required for Virus-Induced Signaling
(A) Effects of MITA RNAi plasmids on the expression of transfected and endogenous MITA. In the upper panel, 293 cells (13 105) were transfected with expres-
sion plasmids for Flag-MITA and Flag-CARD14 (0.1 mg each), and the indicated RNAi plasmids (1 mg). At 24 hr after transfection, cell lysates were analyzed by
immunoblotting with anti-Flag. In the lower panels, 293 cells (23 105) were transfected with control or MITA RNAi plasmids (2 mg each) for 24 hr. Cell lysates were
then analyzed by immunoblotting with the indicated antibodies. The experiments were repeated for three times with similar results.
(B) Effects of MITA RNAi plasmids on SeV-induced IRF-E activation. 293 cells (1 3 105) were transfected with the indicated RNAi plasmids. Twenty-four hours
after transfection, cells were left uninfected or infected with SeV for 8 hr before luciferase assays were performed. Graphs show mean ± SD, n = 3.
(C) Knockdown of MITA inhibits SeV-induced IRF3 activation. 293 cells (23 105) were transfected with a control or MITA RNAi plasmid. Twelve hours after trans-
fection, cells were selected with puromycin (1 mg/ml) for 24 hr, then infected with SeV or left uninfected for 6 hr. Cell lysates were separated by native (upper panel)
or SDS (bottom-two panels) PAGE and analyzed with the indicated antibodies. The experiments were repeated for three times with similar results.
(D and E) Effects of MITA RNAi on SeV-induced (D) NF-kB and (E) IFN-b promoter activation. Reporter assays were performed similarly as in (B). Graphs show
mean ± SD, n = 3.
(F) MITA RNAi inhibits SeV-induced expression of downstream genes. 293 cells (2 3 105) were transfected with a control or MITA RNAi plasmid (2 mg) for 24 hr
RT-PCR was performed 10 hr after SeV infection. The experiments were repeated for three times with similar results.
(G) MITA RNAi does not inhibit TNF- or IL-1-induced NF-kB activation. 293 cells (1 3 105) were transfected with NF-kB reporter plasmid (0.1 mg) together with
a control or MITA RNAi plasmid (1 mg each). Twenty-four hours after transfection, cells were left untreated or treated with TNFa or IL-1b (20 ng/ml) for 8 hr before
luciferase assays were performed. Graphs show mean ± SD, n = 3.542 Immunity 29, 538–550, October 17, 2008 ª2008 Elsevier Inc.
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MITA Mediates Cellular Antiviral ResponseFigure 4. MITA Is Localized to the Outer Membrane of Mitochondria
(A and B) Cell fractionation and immunoblot analysis of the subcellular fractions. Cell fractionation strategy is shown in (A). 293 cells were infected with SeV or left
uninfected for 2 hr and cell fractions were analyzed by immunoblotting with the indicated antibodies (B). The experiments were repeated for three times with
similar results.
(C) Confocal microscopy of the cellular localization of MITA. 293 cells were transfected with GFP control, N-terminal (GFP-MITA), or C-terminal (MITA-GFP)
GFP-tagged MITA. Transfected cells were stained with the MitoTracker Red and observed by confocal microscopy.
(D) MITA is sensitive to trypsin treatment. The purified mitochondria were treated with trypsin (5 mM) or left untreated and then analyzed by immunoblotting with
the indicated antibodies. The experiments were repeated for three times with similar results.addition, phosphorylated IRF3 was also detected in the mito-
chondrial fraction upon viral infection (Figure S8).
To determine whether MITA is required for recruitment of
TBK1 and IRF3 to VISA, we determined the effects of MITA
knockdown on the association of VISA with TBK1 and IRF3.
Coimmunoprecipitation experiments indicated that knockdown
of MITA impaired SeV-induced association of VISA with TBK1
and IRF3 (Figure 6B). These data suggest that TBK1 and IRF3
are linked to the VISA complex through MITA.
We further determined whether MITA can act as a scaffold
protein for TBK1 and IRF3. We found that MITA markedly
enhanced the interaction between TBK1 and IRF3 in coimmuno-precipitation experiments (Figure 6C). Similarly, MITA also
markedly enhanced the interaction between IKK3 and IRF3
(Figure S9). Further analysis indicated that MITA could dimerize
or oligomerize, depending on its aa 111–160 fragment spanning
the last two putative transmembrane regions (Figure S10). Dele-
tion analysis indicated that aa 81–379 of MITA is important for its
interaction with TBK1 and IRF3, as well as for enhancing the
interaction between TBK1 and IRF3 (Figure S11). Consistently,
this fragment was sufficient for activating IRF-E (Figure 6D).
These data suggest that MITA acts as a scaffold protein for
TBK1 and IRF3 and for linking them to the VISA complex upon
viral infection.(H and I) Effects of MITA on cellular antiviral responses. (H) shows that overexpression of MITA inhibits VSV replication. 293 cells (13 105) were transfected with
the indicated amount of MITA expression plasmids. At 24 hr after transfection, cells were infected with VSV (MOI = 1) and supernatants were harvested at 12 hr
postinfection (hpi). Supernatants were analyzed for VSV production with standard plaque assays. (I) shows that knockdown of MITA increases VSV replication.
Plaque assays were performed as in (H), except that MITA RNAi plasmid (1 mg) was used (**p < 0.001; *p < 0.01). Graphs show mean ± SD, n = 3.Immunity 29, 538–550, October 17, 2008 ª2008 Elsevier Inc. 543
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MITA Mediates Cellular Antiviral ResponseTBK1-Mediated Phosphorylation of MITA Is Critical
for Virus-Triggered IRF3 Activation
During the coimmunoprecipitation experiments, we routinely ob-
served that TBK1 but not its kinase-inactive mutant caused
a shift of MITA to higher molecular weight bands (Figure 6C);
such a shift was due to TBK1 phosphorylation because treat-
ment with phosphatase diminished the shift (Figure 7A). We
made a series of MITA mutants in which one or more potential
phosphorylation residues predicted by the NetPhos program
were mutated to alanines. Immunoblot analysis indicated that
mutation of S324 and 326 or S358 to alanine reduced TBK1-
mediated phosphorylation of MITA (Figure 7B). Interestingly,
the MITA(S358A) mutant failed to activate IRF-E and acted as
a dominant-negative mutant that dramatically inhibited SeV-
induced IRF-E activation (Figure 7C). We further confirmed that
S358 is a true phosphorylation site targeted by TBK1 by mass
spectrometry analysis (Figure S12). Consistent with its inability
to activate IRF-E, the mutation of S358 to alanine impaired the
ability of MITA to interact with TBK1 and to enhance the interac-
tion between TBK1 and IRF3 (Figure S13).
To determine whether MITA is a true phosphoprotein, we per-
formed 32P in vivo labeling experiments. The results indicated
that MITA was basally phosphorylated and that its phosphoryla-
tion was enhanced after viral infection (Figure 7D). Cotransfec-
tion of a kinase-inactive TBK1 mutant inhibited virus-induced
MITA phosphorylation. Mutation of the putative TBK1 target sites
also reduced the phosphorylation of MITA in response to SeV
infection (Figure 7E). Consistently, MITA activated IRF-E in
wild-type but not Tbk1/ mouse embryonic fibroblasts
(MEFs), whereas ectopic expression of TBK1 restored the ability
of MITA to activate IRF-E in Tbk1/ cells (Figure 7F). Taken
together, these data suggest that viral infection causes TBK1-
mediated MITA phosphorylation, which is important for virus-
triggered IRF3 activation.
DISCUSSION
Previous studies have demonstrated that the mitochondrial pro-
tein VISA plays an essential role in virus-triggered induction of
type I IFNs and innate antiviral immunity. In this study, we iden-
tified MITA as a VISA-associated mitochondrial protein that
functions downstream of VISA in the IRF3-activation pathway.Similar to VISA, MITA is ubiquitously expressed in all exam-
ined human tissues, and such an expression is consistent with
the notion that type I IFNs are rapidly induced by viruses in all
cell types. Overexpression of MITA activated IRF3. Conversely,
knockdown of endogenous MITA abolished virus-triggered ac-
tivation of IRF3 and induction of IFNB1 and other IRF3-depen-
dent downstream genes. Consistently, overexpression of
MITA inhibited viral replication, whereas knockdown of MITA
had an opposite effect. These data demonstrate that MITA is
a critical component in the virus-triggered IRF3-activation path-
way and cellular antiviral response. Although overexpression of
MITA did not activate NF-kB, knockdown of MITA inhibited
virus-triggered NF-kB activation. This observation suggests
a potential crosstalk between virus-triggered IRF3 and NF-kB
activation pathways at the MITA level. In this context, it has
been demonstrated that the IKK regulatory subunit NEMO(IKKg)
is required for virus-triggered IRF3 activation (Zhao et al., 2007).
We attempted to investigate the mechanism that leads to MITA
involvement in the virus-triggered NF-kB activation pathway.
However, coimmunoprecipitation experiments failed to detect
an interaction between MITA and downstream proteins known
to be involved in virus-triggered NF-kB activation, including
TRAF6, IKKa, IKKb, IKKg, TRADD, FADD, and RIP. How MITA
is involved in virus-triggered NF-kB activation is currently
unknown.
Structural analysis indicates that MITA contains four trans-
membrane regions but lacks a conserved N-terminal signal pep-
tide or mitochondrial targeting sequence. Biochemical and
immunofluorescent-staining experiments suggest that MITA is
localized to the outer membrane of mitochondria and that the
third transmembrane region is important for its mitochondrial lo-
calization. Interestingly, VISA also lacks a detectable N-terminal
mitochondrial targeting sequence, and its mitochondrial locali-
zation requires its C-terminal transmembrane region (Seth
et al., 2005). Coimmunoprecipitation experiments indicated that
MITA was constitutively associated with VISA. Deletion analysis
indicates that the C terminus of VISA (aa 360–540) and the region
spanning the third and fourth transmembrane domains of MITA
(aa 111–160) were required for their interaction and localization
to the mitochondria. These observations suggest that MITA
and VISA are constitutively localized to the outer membrane of
mitochondria as a complex.Figure 5. MITA Interacts with VISA and Is Recruited to RIG-I
(A) MITA interacts with VISA. 293 cells (23 106) were transfected with the indicated plasmids (8 mg each). Cell lysates were immunoprecipitated with anti-Flag or
control IgG. The immunoprecipitates were analyzed by immunoblotting with anti-HA (top panel). The expression of the transfected proteins were analyzed by
immunoblotting with anti-HA and anti-Flag (middle and bottom panels) respectively.
(B) MITA interacts with VISA in untransfected cells. 293 cells (13 108) were infected with SeV or left uninfected for 2 hr. Cells were lysed and immunoprecipitation
and immunoblot analysis were performed with the indicated antibodies.
(C) Domain mapping of the VISA-MITA interaction. The experiments were performed similarly as in (A).
(D) VISA RNAi inhibits RIG-I- but not MITA-mediated IRF-E activation. 293 cells (1 3 105) were transfected with the indicated plasmids (1 mg each). Luciferase
assays were performed 24 hr after transfection. Graphs show mean ± SD, n = 3.
(E) Knockdown of MITA inhibits VISA- but not TRIF- and TBK1-mediated signaling. 293 cells (13 105) were first transfected with a MITA RNAi or control plasmid
(1 mg). One day later, cells were selected with puromycin (1 mg/ml) for 24 hr and then retransfected with IRF-E luciferase and the indicated expression plasmids
(0.1 mg each). Luciferase assays were performed 24 hr after the second transfection. Graphs show mean ± SD, n = 3.
(F) VISA mediates the interaction between RIG-I and MITA. 293 cells (23 106) were transfected with the indicated plasmids (8 mg each). Twenty hours after trans-
fection, immunoprecipitation and immunoblot analysis were performed with the indicated antibodies.
(G) MITA is associated with RIG-I through VISA. 293 cells were left untransfected or transfected with the VISA RNAi plasmid. The cells were then treated with SeV
or left untreated for 2 hr before immunoprecipitation and immunoblot analysis were performed with the indicated antibodies.
For (A), (B), (C), (F), and (G), the experiments were repeated for three times with similar results.Immunity 29, 538–550, October 17, 2008 ª2008 Elsevier Inc. 545
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MITA Mediates Cellular Antiviral ResponseFigure 6. MITA Links IRF3 and TBK1 to the VISA-Associated Complex
(A) MITA interacts with TBK1, IKK3, and IRF3/7. 293 cells (2 3 106) were transfected with the indicated expression plasmids (8 mg each), and coimmunopreci-
pitation experiments were performed with the indicated antibodies.
(B) TBK1 and IRF3 are recruited to VISA throughMITA after viral infection. Upper panels show endogenous association of MITA with TBK1 and IRF3. As shown in
the lower panels, knockdown of MITA impairs viral-infection-induced recruitment of TBK1 and IRF3 to VISA. 293 cells (13 108) were untransfected (upper panels)
or transfected with control or MITA RNAi plasmid (lower panels). Cells were infected with SeV or left untreated for 2 hr as indicated before coimmunoprecipitation
experiments were performed.
(C) MITA enhances the interaction between TBK1 and IRF3. 293 cells (23 106) were transfected with the indicated plasmids (8 mg each). Immunoprecipitation and
immunoblot analysis were performed with the indicated antibodies.
(D) Domain mapping of MITA-mediated IRF-E activation. Reporter assays were performed as in Figure 2B. Graphs show mean ± SD, n = 3.
For (A–C), the experiments were repeated for three times with similar results.Several lines of experiments suggest that MITA acts down-
stream of VISA and represents the branching site for VISA-medi-
ated IRF3-activation pathway. First, overexpression of VISA ac-
tivated both NF-kB and IRF3, whereas MITA only activates IRF3.
Second, knockdown of MITA inhibited VISA- but not TRIF- and
TBK1-mediated IRF-E activation, whereas knockdown of VISA
has no effects on MITA-mediated IRF-E activation. Third, MITA546 Immunity 29, 538–550, October 17, 2008 ª2008 Elsevier Inc.is associated with RIG-I in a viral-infection-dependent manner,
and this association was diminished by knockdown of VISA.
Coimmunoprecipitation experiments indicated that IRF3 was
constitutively associated with MITA, whereas TBK1 was re-
cruited to MITA upon viral infection. In mammalian overexpres-
sion system, TBK1 interacted with IRF3 weakly and this interac-
tion was dramatically enhanced by MITA. Both TBK1 and IRF3
Immunity
MITA Mediates Cellular Antiviral ResponseFigure 7. TBK1-Mediated Phosphorylation of MITA Is Critical for Virus-Triggered IRF3 Activation
(A) Phosphorylation of MITA by TBK1 is abolished by calf intestine phosphatase (CIP) treatment. 293 cells (2 3 106) were transfected with the indicated
plasmids (8 mg each). Cell lysates were immunoprecipitated with anti-Flag. The immunoprecipitates were treated with buffer or CIP and analyzed by immu-
noblot with anti-Flag (upper panel). Expression of the transfected proteins were analyzed by immunoblots with anti-Flag (middle panel) or anti-HA (bottom
panel).
(B) Mutation analysis of potential TBK1 phosphorylation sites. 293 cells were transfected with the indicated plasmids and immunoblot analysis was
performed with the indicated antibodies.
(C) Effects of the MITA mutants on SeV-induced IRF-E activation. 293 cells (1 3 105) were transfected with the indicated plasmids (0.5 mg each). Twenty-
four hours after transfection, cells were infected with SeV or left uninfected for 8 hr before luciferase assays were performed. Graphs show mean ± SD,
n = 3.
(D) Endogenous MITA is phosphorylated in vivo. 293 cells (2 3 107) were treated with SeV or left untreated for 2 hr and then labeled with 32P orthophosphate.
The cell lysates were immunoprecipitated with anti-MITA antibody or control IgG. The immunoprecipitates were analyzed by SDS-PAGE and autoradiogra-
phy (upper panel). The level of phosphorylation of MITA was quantitated by the Bio-Rad Quantity One program, and fold activity was shown. Expression of
MITA protein was detected by immunoblot analysis (lower panel).
(E) Phosphorylation of MITA is blocked by TBK1-KA mutant. 293 cells (1 3 107) were transfected with the indicated expression plasmids (8 mg each) for
20 hr, treated with SeV or left untreated for 2 hr, and then labeled with 32P orthophosphate. The cell lysates were immunoprecipitated with anti-Flag.
The immunoprecipitates were analyzed and MITA phosphorylation was quantitated as in (D) (upper panel). Expression of transfected proteins was detected
by immunoblot analysis with anti-HA (middle panel) or anti-Flag (lower panel).
(F) MITA activates IRF-E in wild-type but not Tbk1/ mouse embryonic fibroblasts (MEFs). MEFs (1 3 105) were transfected with the indicated plasmids
(1 mg each) and IRF-E reporter plasmids (0.2 mg). Reporter assays were performed 24 hr after transfection. Graphs show mean ± SD, n = 3.
For (A), (B), (D), and (E), the experiments were repeated for three times with similar results.were recruited to VISA in a viral-infection-dependent process.
Because knockdown of MITA impaired the association of VISA
with TBK1 and IRF3, it suggests that MITA acts as the link for
the recruitment of TBK1 and IRF3 to the VISA complex. Collec-tively, these studies suggest that the mitochondrial-mem-
brane-bound and VISA-associated MITA provides a scaffold
for assembly of a complex activating the IRF3 arm of virus-trig-
gered signaling. In our previous report (Xu et al., 2005) and theImmunity 29, 538–550, October 17, 2008 ª2008 Elsevier Inc. 547
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MITA Mediates Cellular Antiviral Responsecurrent study, we found that VISA is associated with IRF3 in a
viral-infection-dependent manner, whereas MITA interacts with
VISA and IRF3 constitutively. The simplest explanation for these
observations is that two distinct complexes exist on the
mitochondrial membrane under physiological conditions: the
VISA-MITA and MITA-IRF3 complexes. After viral infection,
these two complexes may be brought together by MITA-MITA
interaction. In this context, we demonstrated that MITA can
self-oligomerize.
MITA was phosphorylated by TBK1 and the phosphorylation
was increased after viral infection. Ser358 of MITA was a critical
target of TBK1 because the MITA(S358A) mutant failed to acti-
vate IRF-E and acted as a dominant-negative mutant to inhibit
SeV-induced IRF-E activation. Consistently, MITA(S358A) also
lost its ability to interact with TBK1 and to enhance the interac-
tion between TBK1 and IRF3. The simplest explanation for these
observations is that upon viral infection, TBK1 is recruited to the
VISA-MITA-IRF3 complex, in which TBK1 first phosphorylates
MITA, a step required for its subsequent phosphorylation of
IRF3. Consistently, MITA activates IRF-E in wild-type but not
Tbk1/ mouse embryonic fibroblasts.
In our experiments, we found that mutation of the three serine
residues to alanine (MITA3A) did not completely abolish the
phosphorylation of MITA by TBK1. In addition, phosphorylation
of MITA3A mutant was still increased after viral infection, al-
though to a much lower degree in comparison to wild MITA.
The simplest explanation for this observation is that additional
TBK1 phosphorylation sites exist in MITA.
Various studies have indicated that TBK1 is a ubiquitously ex-
pressed kinase that is required for virus-triggered induction of
type I IFNs. In contrast, expression of IKK3 is limited to certain
immune cells and is undetectable in most other cell types under
physiological conditions (Akira et al., 2006; Honda et al., 2006;
Huang et al., 2005; Lin et al., 2006a; Meylan et al., 2005). It
has been suggested that IKK3 is induced by viral infection
and that the induced IKK3 functions in a redundant role to its
ubiquitous counterpart, TBK1, in the activation of IRF3 and
IRF7. Gene-deletion studies have confirmed that IKK3 is not re-
quired for virus-triggered induction of type I IFNs, but is required
for type I IFN-induced activation of STAT1 and induction of a sub-
set of type I IFN-stimulated genes (Hemmi et al., 2004; Perry
et al., 2004; Tenoever et al., 2007). Similarly, IRF3 is ubiquitously
expressed, whereas IRF7 is induced after viral infection. There-
fore, in most cell types, both IKK3 and IRF7 are not required for
the first wave of induction of type I IFNs but are involved in the
amplification of type I IFNs after viral infection. Because of these
reasons, we performed detailed studies on the relationship be-
tween MITA and TBK1-IRF3 but not IKK3-IRF7. Nevertheless,
we found MITA could interact with IKK3 and IRF7 and promote
IKK3-IRF3 interaction. These studies suggest that MITA can
act as a scaffold for IKK3 and IRF7 in similar ways as for TBK1
and IRF3 and is probably important for the amplification of
type I IFN induction after viral infection.
On the basis of our findings, we propose a working model on
the role of MITA in virus-triggered signaling. In this model, viral
RNA is recognized by RIG-I and MDA5, which then interact with
the mitochondrial protein VISA. VISA signals IKK-NF-kB
activation through TRAF6 or TRAFDD-FADD-RIP. Concurrently,
VISA interacts with the mitochondrial protein MITA, which inter-548 Immunity 29, 538–550, October 17, 2008 ª2008 Elsevier Inc.acts with IRF3 and recruits TBK1 upon viral infection. Previ-
ously, studies have demonstrated a role for TRAF3 in VISA-
mediated IRF3 activation (Oganesyan et al., 2006; Saha et al.,
2006). In this context, we found that MITA is able to interact
with TRAF3. How TRAF3 is involved in MITA-mediated IRF3
activation is unknown at this time. Once recruited to the VISA-
associated complex, TBK1 phosphorylates MITA and this step
may be important for subsequent phosphorylation of IRF3 by
TBK1. Various studies suggest that virus-triggered type I IFN
signaling pathways are also positively regulated by TRIM25-
mediated ubiquitation of RIG-I (Gack et al., 2007) or negatively
regulated by a divergent groups of cellular or viral proteins,
such as A20 (Lin et al., 2006b), DUBA (Kayagaki et al., 2007),
RNF125 (Arimoto et al., 2007), LGP2 (Yoneyama et al., 2005),
NLRX1 (Moore et al., 2008), DAK (Diao et al., 2007),
SIKE (Huang et al., 2005), Pin1(Saitoh et al., 2006), V proteins
(Andrejeva et al., 2004), and NS3/4A (Meylan et al., 2005).
The identification of MITA as a critical mediator of virus-trig-
gered IRF3 activation and type I IFN expression contributes
to the elucidation of the complicated molecular mechanisms
of cellular antiviral response and further demonstrates the
importance of certain mitochondrial proteins in innate antiviral
immunity.
EXPERIMENTAL PROCEDURES
Expression Cloning
Expression cloning was performed similarly as described (Kawai et al., 2005).
In brief, a human spleen cDNA library (Stratagene) was divided into 150
clones per pool and the plasmid DNA was prepared for IRF-E luciferase
reporter assay with 293 cells. The positive pools were further divided into
subpools of 10 clones, which were tested for their ability to activate IRF-E
in reporter assays. Single clones were isolated from the positive subpools
and again tested for their ability to activate IRF-E in reporter assays. The
positive clones were sequenced and identified by BLAST searches of the
GenBank databases.
Reagents
TNFa and IL-1b (R&D Systems); mouse monoclonal antibodies against Flag,
HA and b-actin (Sigma), TBK1 (Imgenex), AIF, KDEL, Caspase3, COX4, and
H2B (Santa Cruz Biotechnology); rabbit polyclonal antibodies against IRF3
(Santa Cruz Biotechnology); and phospho-IRF3 (Ser396) (Upstate) were pur-
chased from the indicated manufacturers. SeV, VSV, and rabbit anti-VISA
and RIG-I antibodies were previously described (Diao et al., 2007; Huang
et al., 2005; Xu et al., 2005). Huh7 cells (D.-Y. Guo), Tbk/ and wild-type
MEFs (W. Yeh) and pEGFP-C3 (Y. Wu) were provided by the indicated inves-
tigators. Mouse and rabbit anti-MITA antisera were raised against recombi-
nant human MITA (221379) and MITA (161379), respectively.
Constructs
NF-kB, IRF-E/ISRE, and the IFN-b promoter luciferase reporter plasmids, VISA
RNAi plasmid, mammalian expression plasmids for HA- or Flag-tagged VISA
and its mutants RIG-I, TBK1, IKK3, IKKa, IRF3, IRF7, IRF9, IRF3-DN, IRF7-
DN, TRAF3, IKK3-KA, and TBK1-KA were previously described (Diao et al.,
2007; Huang et al., 2005; Xu et al., 2005). Mammalian expression plasmids
for human HA-, Flag- or GFP-tagged MITA and its truncated mutants were
constructed by standard molecular biology techniques.
Transfection and Reporter Gene Assays
The 293 cells (1 3 105) were seeded on 24-well dishes and transfected the
following day by standard calcium phosphate precipitation. In the same exper-
iment, we added empty control plasmid to ensure that each transfection re-
ceives the same amount of total DNA. To normalize for transfection efficiency,
we added 0.01 mg of pRL-TK Renilla luciferase reporter plasmid to each
Immunity
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assay kit (Promega). Firefly luciferase activities were normalized on the basis
of Renilla luciferase activities. All reporter assays were repeated for at least
three times. Data shownwere average values ±SD fromone representative ex-
periment.
Coimmunoprecipitation, Immunoblot Analysis, Native PAGE,
RNA Blot Analysis, and VSV Plaque Assays
These experiments were performed as described (Diao et al., 2007; Huang
et al., 2005; Xu et al., 2005).
RNAi
The RNAi plasmids targeting human MITA mRNA were purchased from Ori-
gene. The target sequences were as following: MITA RNAi #1: 50-gcaacagca
tctatgagcttctggagaac-30; #2: 50-gtgcagtgagccagcggctgtatattctc;-30 #3: 50-gct
ggcatggtcatattacatcggatatc-30.
RT-PCR
RT-PCR was performed as described (Huang et al., 2005). Gene-specific
primer sequences for IFN-b and GAPDH were as described (Huang et al.,
2005) or were as follows: ISG56, forward: 50-acggctgcctaatttacagc-30, and
reverse: 50-agtggctgatatctgggtgc-30; ISG15, forward: 50-atgggctgggacctga
cgg-30, and reverse: 50-ttagctccgcccgccaggct-30.
Subcellular Fractionation
The 293 cells (53 107) infectedwith SeV or left uninfected for 2 hr were washed
with PBS and lysed by douncing for 20 times in 2 ml homogenization buffer
(10 mM Tris-HCl [pH 7.4], 2 mM MgCl2, 10 mM KCl, and 250 mM sucrose).
The homogenate was centrifuged at 500 g for 10 min, and the pellet (P5)
was saved as crude nuclei. The supernatant (S5) was centrifuged at 5000 g
for 10 min to precipitate crude mitochondria (P5K). The supernatant (S5K)
was further centrifuged at 50,000 g for 60 min for S50K and P50K generation.
Immunofluorescent Confocal Microscopy
The transfected 293 cells were incubated with the MitoTracker Red (Molecular
Probes) for 30 min. The cells were then fixed with 4% paraformaldehyde
for 10 min and observed with a Leica confocal microscope under a 3100 oil
objective.
32P In Vivo Labeling
Cells were infected with SeV or left untreated for 2 hr and then starved in phos-
phate-free DMEM/1% dialyzed FBS for 1 hr. Afterward, the cells were col-
lected and labeled with 32P orthophosphate (Perkin Elmer) at a concentration
of 1 mCi/ml for 1 hr. The cells were then lysed and the lysates were immuno-
precipitated with the indicated antibodies. The immunoprecipitates were ana-
lyzed by SDS-PAGE and autoradiography. Before labeling, we took a small
fraction of cells for immunoblot analysis to detect protein expression.
SUPPLEMENTAL DATA
Supplemental Data include thirteen figures and can be found with this article
online at http://www.immunity.com/cgi/content/full/29/4/538/DC1/.
ACKNOWLEDGMENTS
We thank L.-G. Xu, L. Guo, F. Yang, P. Xue, and R.-P. Wang for technique help,
W.-C. Yeh, D.-Y. Guo, and Y. Wu for reagents. This work was supported by
grants from the Chinese 973 program (#2006CB504301 and #2009CB522506),
the National Natural Science Foundation of China (#30630019 and
#30700431), and the Chinese 863 program (#2006AA02A306).
Received: May 29, 2008
Revised: September 2, 2008
Accepted: September 10, 2008
Published online: September 25, 2008REFERENCES
Akira, S., Uematsu, S., and Takeuchi, O. (2006). Pathogen recognition and
innate immunity. Cell 124, 783–801.
Alexopoulou, L., Holt, A.C., Medzhitov, R., and Flavell, R.A. (2001). Recogni-
tion of double-stranded RNA and activation of NF-kappaB by Toll-like receptor
3. Nature 413, 732–738.
Andrejeva, J., Childs, K.S., Young, D.F., Carlos, T.S., Stock, N., Goodbourn,
S., and Randall, R.E. (2004). The V proteins of paramyxoviruses bind the
IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta
promoter. Proc. Natl. Acad. Sci. USA 101, 17264–17269.
Arimoto, K., Takahashi, H., Hishiki, T., Konishi, H., Fujita, T., and Shimotohno,
K. (2007). Negative regulation of the RIG-I signaling by the ubiquitin ligase
RNF125. Proc. Natl. Acad. Sci. USA 104, 7500–7505.
Diao, F., Li, S., Tian, Y., Zhang, M., Xu, L.G., Zhang, Y., Wang, R.P., Chen, D.,
Zhai, Z., Zhong, B., et al. (2007). Negative regulation of MDA5- but not RIG-I-
mediated innate antiviral signaling by the dihydroxyacetone kinase. Proc. Natl.
Acad. Sci. USA 104, 11706–11711.
Durbin, J.E., Fernandez-Sesma, A., Lee, C.K., Rao, T.D., Frey, A.B., Moran,
T.M., Vukmanovic, S., Garcia-Sastre, A., and Levy, D.E. (2000). Type I IFN
modulates innate and specific antiviral immunity. J. Immunol. 164, 4220–4228.
Fitzgerald, K.A., McWhirter, S.M., Faia, K.L., Rowe, D.C., Latz, E., Golenbock,
D.T., Coyle, A.J., Liao, S.M., and Maniatis, T. (2003). IKKepsilon and TBK1
are essential components of the IRF3 signaling pathway. Nat. Immunol. 4,
491–496.
Gack, M.U., Shin, Y.C., Joo, C.H., Urano, T., Liang, C., Sun, L., Takeuchi, O.,
Akira, S., Chen, Z., Inoue, S., and Jung, J.U. (2007). TRIM25 RING-finger E3
ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 446,
916–920.
Han, K.J., Su, X., Xu, L.G., Bin, L.H., Zhang, J., and Shu, H.B. (2004). Mecha-
nisms of the TRIF-induced interferon-stimulated response element and NF-
kappaB activation and apoptosis pathways. J. Biol. Chem. 279, 15652–15661.
Hemmi, H., Takeuchi, O., Sato, S., Yamamoto, M., Kaisho, T., Sanjo, H.,
Kawai, T., Hoshino, K., Takeda, K., and Akira, S. (2004). The roles of two Ikap-
paB kinase-related kinases in lipopolysaccharide and double stranded RNA
signaling and viral infection. J. Exp. Med. 199, 1641–1650.
Hiscott, J. (2007). Convergence of the NF-kappaB and IRF pathways in the
regulation of the innate antiviral response. Cytokine Growth Factor Rev. 18,
483–490.
Honda, K., Takaoka, A., and Taniguchi, T. (2006). Type I interferon [corrected]
gene induction by the interferon regulatory factor family of transcription
factors. Immunity 25, 349–360.
Hornung, V., Ellegast, J., Kim, S., Brzozka, K., Jung, A., Kato, H., Poeck, H.,
Akira, S., Conzelmann, K.K., Schlee, M., et al. (2006). 50-Triphosphate RNA
is the ligand for RIG-I. Science 314, 994–997.
Huang, J., Liu, T., Xu, L.G., Chen, D., Zhai, Z., and Shu, H.B. (2005). SIKE is an
IKK epsilon/TBK1-associated suppressor of TLR3- and virus-triggered IRF-3
activation pathways. EMBO J. 24, 4018–4028.
Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K.,
Uematsu, S., Jung, A., Kawai, T., Ishii, K.J., et al. (2006). Differential roles of
MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441,
101–105.
Katze, M.G., He, Y., and Gale, M., Jr. (2002). Viruses and interferon: A fight for
supremacy. Nat. Rev. Immunol. 2, 675–687.
Kawai, T., Takahashi, K., Sato, S., Coban, C., Kumar, H., Kato, H., Ishii, K.J.,
Takeuchi, O., and Akira, S. (2005). IPS-1, an adaptor triggering RIG-I- and
Mda5-mediated type I interferon induction. Nat. Immunol. 6, 981–988.
Kayagaki, N., Phung, Q., Chan, S., Chaudhari, R., Quan, C., O’Rourke, K.M.,
Eby, M., Pietras, E., Cheng, G., Bazan, J.F., et al. (2007). DUBA: A deubiquiti-
nase that regulates type I interferon production. Science 318, 1628–1632.
Kumar, H., Kawai, T., Kato, H., Sato, S., Takahashi, K., Coban, C., Yamamoto,
M., Uematsu, S., Ishii, K.J., Takeuchi, O., and Akira, S. (2006). Essential role of
IPS-1 in innate immune responses against RNA viruses. J. Exp. Med. 203,
1795–1803.Immunity 29, 538–550, October 17, 2008 ª2008 Elsevier Inc. 549
Immunity
MITA Mediates Cellular Antiviral ResponseLevy, D.E., and Garcia-Sastre, A. (2001). The virus battles: IFN induction of the
antiviral state and mechanisms of viral evasion. Cytokine Growth Factor Rev.
12, 143–156.
Levy, D.E., and Marie, I.J. (2004). RIGging an antiviral defense–it’s in the
CARDs. Nat. Immunol. 5, 699–701.
Lin, R., Lacoste, J., Nakhaei, P., Sun, Q., Yang, L., Paz, S., Wilkinson, P., Jul-
kunen, I., Vitour, D., Meurs, E., and Hiscott, J. (2006a). Dissociation of a MAV-
S/IPS-1/VISA/Cardif-IKKepsilon molecular complex from the mitochondrial
outer membrane by hepatitis C virus NS3–4A proteolytic cleavage. J. Virol.
80, 6072–6083.
Lin, R., Yang, L., Nakhaei, P., Sun, Q., Sharif-Askari, E., Julkunen, I., and
Hiscott, J. (2006b). Negative regulation of the retinoic acid-inducible gene
I-induced antiviral state by the ubiquitin-editing protein A20. J. Biol. Chem.
281, 2095–2103.
Maniatis, T., Falvo, J.V., Kim, T.H., Kim, T.K., Lin, C.H., Parekh, B.S., and Wa-
thelet, M.G. (1998). Structure and function of the interferon-beta enhanceo-
some. Cold Spring Harb. Symp. Quant. Biol. 63, 609–620.
Matsui, K., Kumagai, Y., Kato, H., Sato, S., Kawagoe, T., Uematsu, S., Take-
uchi, O., and Akira, S. (2006). Cutting edge: Role of TANK-binding kinase 1
and inducible IkappaB kinase in IFN responses against viruses in innate
immune cells. J. Immunol. 177, 5785–5789.
Meylan, E., Curran, J., Hofmann, K., Moradpour, D., Binder, M., Bartenschl-
ager, R., and Tschopp, J. (2005). Cardif is an adaptor protein in the RIG-I
antiviral pathway and is targeted by hepatitis C virus. Nature 437, 1167–1172.
Michallet, M.C., Meylan, E., Ermolaeva, M.A., Vazquez, J., Rebsamen, M.,
Curran, J., Poeck, H., Bscheider, M., Hartmann, G., Konig, M., et al. (2008).
TRADD protein is an essential component of the RIG-like helicase antiviral
pathway. Immunity 28, 651–661.
Moore, C.B., Bergstralh, D.T., Duncan, J.A., Lei, Y., Morrison, T.E., Zimmer-
mann, A.G., Accavitti-Loper, M.A., Madden, V.J., Sun, L., Ye, Z., et al.
(2008). NLRX1 is a regulator of mitochondrial antiviral immunity. Nature 451,
573–577.
Nakaya, T., Sato, M., Hata, N., Asagiri, M., Suemori, H., Noguchi, S., Tanaka,
N., and Taniguchi, T. (2001). Gene induction pathways mediated by distinct
IRFs during viral infection. Biochem. Biophys. Res. Commun. 283, 1150–1156.
Navarro, L., Mowen, K., Rodems, S., Weaver, B., Reich, N., Spector, D., and
David, M. (1998). Cytomegalovirus activates interferon immediate-early
response gene expression and an interferon regulatory factor 3-containing
interferon-stimulated response element-binding complex. Mol. Cell. Biol. 18,
3796–3802.
Oganesyan, G., Saha, S.K., Guo, B., He, J.Q., Shahangian, A., Zarnegar, B.,
Perry, A., and Cheng, G. (2006). Critical role of TRAF3 in the Toll-like recep-
tor-dependent and -independent antiviral response. Nature 439, 208–211.
Oshiumi, H., Matsumoto, M., Funami, K., Akazawa, T., and Seya, T. (2003).
TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-medi-
ated interferon-beta induction. Nat. Immunol. 4, 161–167.
Perry, A.K., Chow, E.K., Goodnough, J.B., Yeh, W.C., and Cheng, G. (2004).
Differential requirement for TANK-binding kinase-1 in type I interferon
responses to toll-like receptor activation and viral infection. J. Exp. Med.
199, 1651–1658.550 Immunity 29, 538–550, October 17, 2008 ª2008 Elsevier Inc.Pichlmair, A., Schulz, O., Tan, C.P., Naslund, T.I., Liljestrom, P., Weber, F., and
Reis e Sousa, C. (2006). RIG-I-mediated antiviral responses to single-stranded
RNA bearing 50-phosphates. Science 314, 997–1001.
Saha, S.K., Pietras, E.M., He, J.Q., Kang, J.R., Liu, S.Y., Oganesyan, G., Sha-
hangian, A., Zarnegar, B., Shiba, T.L., Wang, Y., and Cheng, G. (2006). Regu-
lation of antiviral responses by a direct and specific interaction between TRAF3
and Cardif. EMBO J. 25, 3257–3263.
Saitoh, T., Tun-Kyi, A., Ryo, A., Yamamoto, M., Finn, G., Fujita, T., Akira, S.,
Yamamoto, N., Lu, K.P., and Yamaoka, S. (2006). Negative regulation of inter-
feron-regulatory factor 3-dependent innate antiviral response by the prolyl
isomerase Pin1. Nat. Immunol. 7, 598–605.
Seth, R.B., Sun, L., Ea, C.K., and Chen, Z.J. (2005). Identification and charac-
terization of MAVS, a mitochondrial antiviral signaling protein that activates
NF-kappaB and IRF 3. Cell 122, 669–682.
Sun, Q., Sun, L., Liu, H.H., Chen, X., Seth, R.B., Forman, J., and Chen, Z.J.
(2006). The specific and essential role of MAVS in antiviral innate immune
responses. Immunity 24, 633–642.
Tenoever, B.R., Ng, S.L., Chua, M.A., McWhirter, S.M., Garcia-Sastre, A., and
Maniatis, T. (2007). Multiple functions of the IKK-related kinase IKKepsilon in
interferon-mediated antiviral immunity. Science 315, 1274–1278.
Wathelet, M.G., Clauss, I.M., Nols, C.B., Content, J., and Huez, G.A. (1987).
New inducers revealed by the promoter sequence analysis of two interferon-
activated human genes. Eur. J. Biochem. 169, 313–321.
Wathelet, M.G., Lin, C.H., Parekh, B.S., Ronco, L.V., Howley, P.M., and Mani-
atis, T. (1998). Virus infection induces the assembly of coordinately activated
transcription factors on the IFN-beta enhancer in vivo. Mol. Cell 1, 507–518.
Xu, L.G., Wang, Y.Y., Han, K.J., Li, L.Y., Zhai, Z., and Shu, H.B. (2005). VISA is
an adapter protein required for virus-triggered IFN-beta signaling. Mol. Cell 19,
727–740.
Yamamoto, M., Sato, S., Hemmi, H., Hoshino, K., Kaisho, T., Sanjo, H., Take-
uchi, O., Sugiyama, M., Okabe, M., Takeda, K., and Akira, S. (2003). Role of
adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway.
Science 301, 640–643.
Yamamoto, M., Sato, S., Mori, K., Hoshino, K., Takeuchi, O., Takeda, K., and
Akira, S. (2002). Cutting edge: A novel Toll/IL-1 receptor domain-containing
adapter that preferentially activates the IFN-beta promoter in the Toll-like
receptor signaling. J. Immunol. 169, 6668–6672.
Yoneyama, M., Kikuchi, M., Matsumoto, K., Imaizumi, T., Miyagishi, M., Taira,
K., Foy, E., Loo, Y.M., Gale, M., Jr., Akira, S., et al. (2005). Shared and unique
functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral
innate immunity. J. Immunol. 175, 2851–2858.
Yoneyama, M., Kikuchi, M., Natsukawa, T., Shinobu, N., Imaizumi, T., Miya-
gishi, M., Taira, K., Akira, S., and Fujita, T. (2004). The RNA helicase RIG-I
has an essential function in double-stranded RNA-induced innate antiviral
responses. Nat. Immunol. 5, 730–737.
Zhao, T., Yang, L., Sun, Q., Arguello, M., Ballard, D.W., Hiscott, J., and Lin, R.
(2007). The NEMO adaptor bridges the nuclear factor-kappaB and interferon
regulatory factor signaling pathways. Nat. Immunol. 8, 592–600.
